Angiovist 370 and Quadriplegia - a phase IV clinical study of FDA data


We study 2,890 people who take Angiovist 370 or have Quadriplegia. No report of Quadriplegia is found in people who take Angiovist 370.

The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 07, 2023

No report is found.

What is Angiovist 370?

Angiovist 370 has active ingredients of diatrizoate meglumine; diatrizoate sodium.

What is Quadriplegia?

Quadriplegia (a four limb paralysis) is found to be associated with 1,150 drugs and 829 conditions by eHealthMe.

Do you take Angiovist 370 and have Quadriplegia?

Check whether Quadriplegia is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Quadriplegia and when was it recovered:

Expand to all the drugs that have ingredients of diatrizoate meglumine; diatrizoate sodium:

Alternative drugs to, pros and cons of Angiovist 370:

Quadriplegia treatments and more:

COVID vaccines that are related to Quadriplegia:

All the drugs that are associated with Quadriplegia:

All the conditions that are associated with Quadriplegia:

How the study uses the data?

The study uses data from the FDA. It is based on diatrizoate meglumine; diatrizoate sodium (the active ingredients of Angiovist 370) and Angiovist 370 (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: